SUNNYVALE, Calif., March 16 /PRNewswire/ -- B-Bridge International and Pointilliste have partnered to commercialize research products based on Pointilliste's self-assembling antibody array technology platform. The Universal Canvas(TM) technology enables researchers to create their own customized arrays containing whatever sets of antibodies and/or proteins they choose.
Essentially, the Universal Canvas(TM) allows researchers to multiplex nine ELISAs into a single plate. 96 arrays, each with duplicate positions for the nine selected antibodies plus embedded controls, are located in the wells of a 96-well plate. After preparation, the nine antibodies are simply pooled and added to each well where they sort themselves onto the array. The assay is run just like a standard ELISA. The arrays are visualized using a standard imaging system and interpreted using provided software.
According to Dr. Dana Ault-Riche, CEO of Pointilliste, "Pointilliste's primary interest is to use this technology to develop personalized antibody-based therapeutics. However, we realized that the flexibility of our technology platform offers a unique and powerful proteomics tool for basic researchers. We teamed up with B-Bridge to help us commercialize our technology for the research products market."
Dr. Paul Diehl, Director of Marketing and Sales for B-Bridge International commented, "We are excited to work with Pointilliste since we see real potential for this platform to provide researchers with better results faster since it generates much more data with the same amount of effort as a traditional ELISA. We are delighted to provide this capability to our customers."
Products based on the Universal Canvas(TM) platform will be available from B-Bridge in a few weeks. B-Bridge currently sells a Human Th1/Th2 Cytokine Antibody Array designed by Pointilliste.
Pointilliste -- founded in 2000 in Mountain View, CA -- is developing a process to enable cancer patients to fight their diseases with tailor-made drugs. Pointilliste utilizes its proprietary Universal Canvas(TM) technology to display and rapidly screen billions of unique potential drugs.
B-Bridge International -- founded in 2000 and based in Sunnyvale, California -- provides quality tools and technology to advance global discovery in biotechnology. With access to worldwide markets in the academic, government, pharmaceutical, and biotechnology sectors, B-Bridge fosters the development and availability of new technology through manufacturing, distribution, and incubation.
To learn more about B-Bridge International, please visit http://www.b-bridge.com/.
To learn more about Pointilliste, please visit http://www.pointilliste.com/.
Contact: Paul Diehl of B-Bridge, +1-408-735-7727, ext. 49, or email@example.com; or Dr. Dana Ault-Riche of Pointilliste, 888-512-2995, ext.101, or firstname.lastname@example.org.
CONTACT: Paul Diehl of B-Bridge, +1-408-735-7727, ext. 49, email@example.com; or Dr. Dana Ault-Riche of Pointilliste, 888-512-2995,ext.101, or firstname.lastname@example.org